Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The ...
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company headquartered in Alameda, California, with a focus on developing innovative implantable drug delivery systems. The company leverages its proprietary NanoPortal™ technology to create miniature, subdermal implants designed to provide consistent, near-constant-rate delivery of therapeutic drugs over extended periods (up to 12 months ...Vivani Medical, Inc. is a clinical-stage biopharmaceutical company headquartered in Alameda, California, with a focus on developing innovative implantable drug delivery systems. The company leverages its proprietary NanoPortal™ technology to create miniature, subdermal implants designed to provide consistent, near-constant-rate delivery of therapeutic drugs over extended periods (up to 12 months or more). This approach aims to address chronic diseases such as type 2 diabetes, obesity, and other conditions where patient adherence to daily medication is a challenge. The company's lead product candidate, NPM-115 (exenatide implant), is in clinical development for the treatment of obesity and type 2 diabetes. Vivani also has a pipeline including other implants for cardiovascular and endocrine indications. The company was originally founded in 2009 as Nano Precision Medical, and in August 2022 it merged with Second Sight Medical Products, which was known for developing visual prostheses. Post-merger, the company was renamed Vivani Medical, Inc., and trades on the Nasdaq Capital Market under the symbol VANI. Adam Mendelsohn, Ph.D., co-founder and CEO, has led the company since its inception. As of 2026, the company has 42 full-time employees. Financially, Vivani is pre-revenue, with a market capitalization of around $120 million, negative operating cash flow, and a strong cash position relative to its burn rate. The company is focused on advancing its clinical trials, starting with the NPM-115 program, and pursuing regulatory approvals to bring its innovative implant technology to market.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-26.6M
-13.3%
+6.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-25.5M
-19.4%
+1.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
119.9%
+9.3%
-1.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.71x
-20.6%
+2.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
